Eurofins Viracor Launches ExPeCT™ anti-CD19 (obe-cel) CAR T-Cell Assay to Advance Proactive Monitoring in Next-Generation Immunotherapy
Eurofins Viracor has launched the ExPeCT™ anti-CD19 (obe-cel) CAR T-cell assay, a new diagnostic solution designed to support proactive monitoring of next-generation CAR T-cell therapies. This non-invasive blood test enables real-time assessment of CAR T-cell expansion and persistence, delivering results in approximately 24 hours after specimen receipt. Developed specifically for testing obecabtagene autoleucel (obe-cel), the assay helps clinicians gain timely, validated insights to support informed therapy decisions.
